This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: The FDA is the primary source of adverse event data and reports. As noted by Dr Trontell, the evaluation of suspect adverse events by the recently initiated RADAR project and the FDA differ. Key distinctions are the RADAR project’s greater frequency of interactions with clinicians; a primary focus on potentially fatal ADRs; and different approaches to analysis, interpretation, causality assessments, and information dissemination.

Two cases illustrate these differences. The FDA identified high rates of pure red cell aplasia with use of the epoetin alfa formulation Eprex, during the years 1998 to 2001.¹ RADAR expanded on these findings and reported that the increase occurred with subcutaneous administration of the human-serum-albumin–free formulation of Eprex primarily to chronic kidney disease patients in England, France, Canada, and Spain.² In a second example, the FDA issued a "Dear Doctor" letter identifying 50 hypersensitivity cases associated with drug-eluting coronary artery stents and retracted an . . . [Full Text of this Article]

Charles L. Bennett, MD, PhD, MPP
cbenne@northwestern.edu
Jesse Brown VA Medical Center
Chicago, IL

Jonathan R. Nebeker, MS, MD
University of Utah School of Medicine
Salt Lake City

Dennis W. Raisch, PhD
VA Cooperative Studies Program Clinical Research Pharmacy
Coordinating Center
Albuquerque, NM

RELATED ARTICLES

The RADAR Project and the FDA
Anne E. Trontell
JAMA. 2005;294(10):1206.
EXTRACT | FULL TEXT  

The Research on Adverse Drug Events and Reports (RADAR) Project
Charles L. Bennett, Jonathan R. Nebeker, E. Allison Lyons, Matthew H. Samore, Marc D. Feldman, June M. McKoy, Kenneth R. Carson, Steven M. Belknap, Steven M. Trifilio, Glen T. Schumock, Paul R. Yarnold, Charles J. Davidson, Andrew M. Evens, Timothy M. Kuzel, Jorge P. Parada, Denis Cournoyer, Dennis P. West, Oliver Sartor, Martin S. Tallman, and Dennis W. Raisch
JAMA. 2005;293(17):2131-2140.
ABSTRACT | FULL TEXT